Nebenwirkungen · Prevenar 20 (previously Apexxnar)
Prevenar 20 suspension for injection in pre-filled syringe Pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) · Abschnitt 4.8 · PDF-Seite 9
HOS-147526 · Präparat HOS-099678
Phase 3 Study B7471006 (Study 1006) evaluated Prevenar 20 in participants ≥ 65 years of age with varying prior pneumococcal status (prior PPSV23, prior Prevenar 13 or prior Prevenar 13 followed by PPSV23). In this study, the most frequently reported adverse reactions for participants were similar in frequency to those described for participants ≥ 60 years of age in Study 1007, with slightly higher injection site pain (61.2%) in participants with prior Prevenar 13, and joint pain (16.8%) in participants with prior Prevenar 13 followed by PPSV23.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-18T11:35:00Z · SHA-256 dfbc64c4baaa139cb8a19b75051b25fafe4ef25223c0b54cadf2fd05f2c80f98 · Passage acaa4a48ffaa840971c6b26911d8e6daccbccbcaa55b217c426c39e0c046d518 · Zeichen 7364–7914 im Abschnitt